MPB vs SRPT · P/E 15, $837.4M cap vs rev $1.90B
Mid Penn Bancorp (MPB) versus Sarepta Therapeutics Inc (SRPT) — a side-by-side from cached financials, not a winner call.
Mid Penn Bancorp (MPB) is a banks - regional company listed on US.
Sarepta Therapeutics Inc (SRPT) is a biotechnology company listed on US.
MPB does not have a complete income-statement cache yet.
Latest reported SRPT revenue for 2024-12-31 was $1.90B. Net income was $235.2M. Revenue was up 53.0% from 2023-12-31 to 2024-12-31. SRPT currently screens at market cap $2.34B.
MPB currently screens at market cap $837.4M and trailing P/E 15.0. SRPT currently screens at market cap $2.34B.
Not investment advice. Open the MPB and SRPT stock pages for the full models.
Not investment advice.